SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
SEC Accession No. 0001193805-17-001100
Filing Date
2017-06-14
Accepted
2017-06-14 06:00:40
Documents
1

Document Format Files

Seq Description Document Type Size
1 AMENDMENT NO. 3 TO THE SCHEDULE 13D sc13da307422cti_06132017.htm SC 13D/A 248582
  Complete submission text file 0001193805-17-001100.txt   250247
Mailing Address 3101 WESTERN AVENUE SUITE 600 SEATTLE WA 98121
Business Address 3101 WESTERN AVENUE SUITE 600 SEATTLE WA 98121 2062827100
CTI BIOPHARMA CORP (Subject) CIK: 0000891293 (see all company filings)

IRS No.: 911533912 | State of Incorp.: WA | Fiscal Year End: 1231
Type: SC 13D/A | Act: 34 | File No.: 005-48459 | Film No.: 17910208
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences

Mailing Address 1 SANSOME ST 30TH FL SAN FRANCISCO CA 94104
Business Address 1 SANSOME ST 30TH FL SAN FRANCISCO CA 94104 3125066500
BIOTECHNOLOGY VALUE FUND L P (Filed by) CIK: 0000918923 (see all company filings)

IRS No.: 363924731 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13D/A
SIC: 6282 Investment Advice
Office of Finance